The Trump administration has halted federal funding for research into PediaFlow, a device intended to assist infants with heart defects. Dr. James Antaki, a biomedical engineering professor at Cornell University, was notified that his grant would not be renewed. PediaFlow is designed as a miniature heart pump intended to support babies with failing hearts, giving them a better chance of survival while awaiting transplants or other treatments.
Congenital heart defects are a leading cause of infant mortality, affecting approximately 1 in 100 babies born in the United States. Current treatment options are limited, highlighting the urgent need for innovative solutions like PediaFlow. The device has shown promising results in preclinical studies, demonstrating its potential to significantly improve outcomes for these vulnerable patients.
Dr. Antaki expressed disappointment with the decision, emphasizing the potential impact on the lives of countless children. He is actively seeking alternative funding sources to continue the research and bring PediaFlow to clinical trials. Advocates for pediatric healthcare are also voicing concerns, urging the government to reconsider its decision and prioritize funding for life-saving medical innovations for children.
Federal Funding Cut Endangers Research for Infant Heart Defect Device
A recent decision by the federal government to halt funding for a critical research grant has put the development of PediaFlow, a device designed to help infants with heart defects, in jeopardy. Dr. James Antaki, a biomedical engineering professor at Cornell University, lost the federal grant that supported the device's development. PediaFlow aims to provide life-saving support to babies suffering from congenital heart conditions. The funding cut raises concerns about the future of pediatric medical innovation.
Source: Read the original article at NBC